Lactobacillus Fermentum (HEM Pharma)(Lactobacillus Fermentum (HEM Pharma)) - 在研适应症：低位前切除综合征，腹泻_专利_临床

概要

基本信息

药物类型

益生菌

别名

+ [2]

靶点-

作用方式

调节剂

作用机制

细菌替代物、微生物调节剂

治疗领域

消化系统疾病其他疾病

在研适应症

低位前切除综合征腹泻

非在研适应症-

原研机构

HEM Pharma, Inc.

在研机构

HEM Pharma, Inc.

非在研机构-

权益机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

7

项与 Lactobacillus Fermentum (HEM Pharma) 相关的临床试验

NCT05527301

/ Not yet recruiting临床2期

A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of HEM1036 in Subjects With Low Anterior Resection Syndrome (LARS)

Double-blind, randomized, placebo controlled phase 2 study to explore the efficacy and safety of HEM1036 in the treatment of subjects with LARS

开始日期2024-01-01

申办/合作机构

HEM Pharma, Inc.

[+1]

CTRI/2023/10/058667

/ Not yet recruiting临床4期

Study on the effects of probiotics lactobacillus fermentum and paracasei in adult allergic rhinitis patients in a tertiary care center - NIL

开始日期2023-10-23

申办/合作机构-

NCT05433857

/ Recruiting临床2期IIT

Evaluation of the Clinical Outcome of Probiotics in Systemic Lupus Erythematosus

Dysbiosis, or disruption of the gut microbiota, leads to the onset of autoimmunity. Increasing data suggest that the gut microbiota is changed in various murine lupus models as well as in human systemic lupus erythematosus SLE patients. Ingestion of lactobacilli, which have immunoregulatory properties, may be a viable strategy for controlling disease development and progression in patients with lupus, such as increasing the remission period and decreasing flare frequency.

开始日期2022-06-10

申办/合作机构

Ain Shams University

100 项与 Lactobacillus Fermentum (HEM Pharma) 相关的临床结果

登录后查看更多信息

100 项与 Lactobacillus Fermentum (HEM Pharma) 相关的转化医学

登录后查看更多信息

100 项与 Lactobacillus Fermentum (HEM Pharma) 相关的专利（医药）

登录后查看更多信息

83

项与 Lactobacillus Fermentum (HEM Pharma) 相关的文献（医药）

2025-07-01·Poultry Science

Boosting antioxidant defense and enhancing product quality by biochar and probiotics under chronic aflatoxicosis in quails

Article

作者: Ghazaghi, Mahmoud ; Bagherzadeh-Kasmani, Farzad ; Raz, Majid ; Mehri, Mehran ; Mokhtarpour, Amir ; Karimi-Torshizi, Mohammad Amir

Aflatoxins, particularly aflatoxin B₁ (AFB₁), are potent mycotoxins adversely affecting poultry performance, health, and product quality. Mitigation strategies are critical for poultry productivity. This study assessed the efficacy of Prosopis farcta biochar and Lactobacillus fermentum in mitigating AFB₁-induced toxicity in quails, with a focus on performance, antioxidant status, and product quality. Two experiments were conducted with quails during growing (7-35 days) and laying (70-98 days) periods under five dietary treatments: Negative Control (basal diet), Positive Control (AFB₁-contaminated diet), and AFB₁ diets supplemented with Mycofix Plus, biochar, or biochar combined with L. fermentum. Growth performance, antioxidant status, meat and egg quality, and liver enzyme activity were evaluated. AFB₁ significantly impaired performance, reduced meat and egg quality, and elevated oxidative stress and liver enzymes (P < 0.01). Supplementation with biochar, particularly in combination with L. fermentum, significantly alleviated these effects, improving body weight, glutathione peroxidase activity, and reducing malondialdehyde and liver enzyme levels (P < 0.01). Biochar and its combination with L. fermentum effectively mitigated aflatoxicosis in quails, enhancing health and productivity metrics. Integrating biochar and L. fermentum in poultry diets is a promising approach to managing mycotoxin challenges, improving economic and product quality outcomes in poultry systems.

2024-12-01·Molecular Biology Reports

Probiotic bacteria protect against indomethacin-induced gastric ulcers through modulation of oxidative stress, inflammation, and apoptosis

Article

作者: Gelen, Volkan ; Makav, Mustafa ; Gedikli, Semin ; Şengül, Emin ; Gelen, Sevda Urçar

BACKGROUNDIndomethacin is an anti-inflammatory drug that causes ulcers on the gastric mucosa due to its use. Probiotic bacteria are live microorganisms, and it has been stated by various studies that these bacteria have antioxidant and anti-inflammatory effects. In this study, we investigated the possible protective effect of various types of probiotic bacteria (Lactobacillus rhamnosus, Lactobacillus fermentum, and Lactobacillus brevis) against acute gastric mucosal damage caused by indomethacin.METHODSControl group - Physiological saline was administered daily for 10 days. Indo group-Physiological saline was administered daily for 10 days. Ranitidine + Indo group 5 mg/kg ranitidine dose was administered daily for 5 days. On day 11, a single dose of 100 mg/kg of indomethacin was given to the same group. Probiotic + Indo group 1 ml/kg of oral probiotic bacteria was administered daily for 10 days. On day 11, a single 100 mg/kg dose of indomethacin was given. After the application, the rats were anesthetized with ketamine xylazine, killed under appropriate conditions, the abdominal cavity was opened and the stomach tissues were removed. The obtained gastric tissues were used in the biochemical and histopathological analyses discussed below. All data were statistically evaluated by one-way ANOVA using SPSS 20.00, followed by Duncan Post hoc test. The data were expressed as mean ± SD. P < 0.05 was considered statistically significant.RESULTSAs a result, the administration of indomethacin caused gastric damage, stimulating oxidative stress, inflammation, and apoptosis. We found that the use of probiotic bacteria reduces oxidative stress (TOC), increases the activity of antioxidant enzymes (TAC), suppresses inflammation (IL-6 and Tnf-α), and inhibits apoptosis (Bax and Bcl-2) (P < 0.05).CONCLUSIONProbiotic treatment can mitigate gastric damage and apoptosis caused by indomethacin-induced gastric damage in rats. Probiotic also enhances the restoration of biochemical oxidative enzymes as it has anti-inflammatory, antioxidant, and antiapoptotic properties.

2024-07-01·Oral Diseases

Lactobacillus fermentum attenuates the alveolar bone loss in ligature‐induced periodontitis in mice

Article

作者: Jung, Bo Hyun ; Lim, Hye Ji ; Lee, Jae‐Kwan ; Yoo, Ki‐Yeon ; Shin, Kum‐Joo ; Lee, Yuni

AbstractObjectiveThis study investigated the effects of Lactobacillus fermentum BELF11 on periodontitis in mice (LIP).MethodsSixty mice were randomly assigned to a control group (CTL), LIP/PBS group (LIP and PBS applied), or LIP/BELF11 group (LIP and L. fermentum BELF11 applied). For 14 days, PBS or L. fermentum BELF11 was applied twice daily to the mice in the LIP/PBS or LIP/BELF11 group, respectively. After 14 days, radiographic, histological, and pro‐inflammatory cytokine assessments were conducted.ResultsThe LIP/PBS and LIP/BELF11 groups demonstrated greater alveolar bone loss than the CTL group (p < 0.05). The LIP/BELF11 group showed significantly reduced alveolar bone loss on the mesial side compared to the LIP/PBS group. Histologically, the LIP/BELF11 group showed consistent patterns of connective tissue fiber arrangement, lower levels of inflammatory infiltration, less alveolar bone loss, and higher alveolar bone density than the LIP/PBS group, despite showing more signs of destruction than the CTL group. The LIP/BELF11 group also exhibited significantly lower levels of pro‐inflammatory cytokines than the LIP/PBS group.ConclusionsL. fermentum BELF11 inhibits alveolar bone loss and periodontitis progression by regulating pro‐inflammatory cytokine production. These findings suggest that L. fermentum BELF11 may be a potential adjunctive therapy in periodontal treatment.

100 项与 Lactobacillus Fermentum (HEM Pharma) 相关的药物交易

登录后查看更多信息